Cost-effectiveness projections of FOLFOX vs. IFL in first-line therapy of metastatic colorectal cancer in the context of the U.S. health care system

3531 Background: A randomized comparison has shown FOLFOX to be superior to the previous U.S. standard of care, IFL for 1st-line therapy (Rx) of metastatic colon cancer. The tradeoffs between costs...